Alterations of serum cytokine levels and their relation with inflammatory markers in candidemia

Medical Mycology

Volumn 53, Issue 3, 2015, Pages 258-268

  Akin, Hicran ^a   Akalin, Halis ^a   Budak, Ferah ^a   Ener, Beyza ^a   Ocakoğlu, Gökhan ^a   Gürcüoğlu, Emel ^b   Göral, Güher ^a   Oral, Haluk Barbaros ^a  

^a ULUDAG UNIVERSITY   (Turkey)

^b Doruk Medical Center   (Turkey)

Author keywords

Candidemia; IL 17; IL 23; PCT; Sepsis

Indexed keywords

ANTIFUNGAL AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; PROCALCITONIN; SERUM AMYLOID A; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; CALCITONIN; PROTEIN PRECURSOR;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BLOOD SAMPLING; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE SEPSIS; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HUMAN; INFLAMMATION; KLUYVEROMYCES MARXIANUS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEPSIS; STATISTICAL SIGNIFICANCE; BLOOD; EVALUATION STUDY; MIDDLE AGED; MIXED INFECTION; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; BIOMARKERS; C-REACTIVE PROTEIN; CALCITONIN; CANDIDEMIA; COINFECTION; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PROTEIN PRECURSORS; SENSITIVITY AND SPECIFICITY; SERUM AMYLOID A PROTEIN; YOUNG ADULT;

EID: 84957410276     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1093/mmy/myu084     Document Type: Article

References (55)

1. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003; 3:685-702
2. Lipsett PA. Surgical critical care: fungal infections in surgical patients. Crit Care Med 2006; 34(9): 215-224
3. Vincent JL, Rello J, Marshall J et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302: 2323-2329
4. Banerjee SN, Emori TG, Culver DH et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med 1991; 91(3B): 86S-89S
5. Fisher-Hoch SP, Hutwagner L. Opportunistic candidiasis: an epidemic of the 1980s. Clin Infect Dis 1995; 21(4): 897-904
6. Hobson RP. The global epidemiology of invasive Candida infections-is the tide turning? J Hosp Infect 2003; 55(3): 159-168
7. Zaoutis TE, Argon J, Chu J et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41(9): 1232-1239
8. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med 2006; 34(3): 857-863
9. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49(9): 3640-3645
10. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43(1): 25-31
11. Grim SA, Berger K, Teng C et al. Timing of susceptibilitybased antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. J Antimicrob Chemother 2012; 67(3): 707-714
12. Martini A, Gottin L, Menestrina N et al. Procalcitonin levels in surgical patients at risk of candidemia. J Infect 2010; 60(6): 425-430
13. Rau BM, Frigerio I, Buchler MW et al. Evaluation of procalcitonin for predicting septic multiorgan failure and overall prognosis in secondary peritonitis: a prospective, international multicenter study. Arch Surg 2007; 142(2): 134-142
14. Meisner M, Tschaikowsky K, Palmaers T et al. Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. Crit Care 1999; 3(1): 45-50
15. Rau BM, Kemppainen EA, Gumbs AA et al. Early assessment of pancreatic infections and overall prognosis in severe acute pancreatitis by procalcitonin (PCT): a prospective international multicenter study. Ann Surg 2007; 245(5): 745-754
16. Hall WH, Ramachandran R, Narayan S et al. An electronic application for rapidly calculating Charlson co-morbidity score. BMC Cancer 2004; 4: 94
17. Goffi L, Saba V, Ghiselli R et al. Preoperative APACHE II and ASA Scores in patients having major general surgical operations: prognostic value and potential clinical applications. Eur J Surg 1999; 165(8): 730-735
18. Horan TC, Gaynes RP. Surveillance of nosocomial infections. In: Mayhall CG (ed.). Hospital Epidemiology and Infection Control, 3rd. ed. Philadelphia: Lippincott Williams & Wilkins, 2004: 1659-1702
19. Povoa P. C-reactive protein: a valuablemarker of sepsis. Intensive Care Med 2002; 28(3): 235-243
20. Sierra R, Rello J, Bailen MA et al. C-reactive protein used as an early indicator of infection in patients with systemic inflammatory response syndrome. Intensive Care Med 2004; 30(11): 2038-2045
21. Uzzan B, Cohen R, Nicolas P et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or travma: a systematic review and meta-analysis. Crit Care Med 2006; 34(7): 1996-2003
22. Tang BM, Eslick GD, Craig JC et al. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007; 7(3): 210-217
23. Simon L, Gauvin F, Amre DK et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systemic review and meta-analysis. Clin Infect Dis 2004; 39(2): 206-217
24. Petrikkos G, Christofilopoulou S, Tentolouris NK et al. Value of measuring serum procalcitonin, C-reactive protein, and mannan antigens to distinguish fungal from bacterial infections. Eur J Clin Microbiol Infect Dis 2005; 24(4): 272-275
25. Charles PE, Dalle F, Aho S et al. Serum procalcitonin measurement contribution to the early diagnosis of candidemia in critically ill patients. Intensive Care Med 2006; 32(10): 1577-1583
26. Fu Y, Chen J, Cai B et al. The use of PCT, CRP, IL-6 and SAA in critically ill patients for an early distinction between candidemia and gram positive/negative bacteremia. J Infect 2012; 64(4): 438-440
27. Charles PE, Ladoire S, Aho S et al. Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either gram negative or gram positive bacteria. BMC Infect Dis 2008; 8: 38
28. Charles EP, Ladoire S, Snauwaer A et al. Impact of previous sepsis on the accuracy of procalcitonin for the early diagnosis of blood stream infection in critically ill patients. BMC Infect Dis 2008; 8: 163
29. Cicarelli DD, Vieira JE, Bensenor FE. Comparison of C-reactive protein and serum amyloid A protein in septic shock patients. Mediators Inflamm 2008; 2008: 631414
30. Çetinkaya M, Özkan H, Köksal N et al. Comparison of serum amyloid A concentrations with those of C-reactive protein and procalcitonin in diagnosis and follow-up of neonatal sepsis in premature infants. J Perinatol 2009; 29(3): 225-231
31. Uçar B, Yıldız B, Aksçit MA et al. Serum amyloid A, procalcitonin, tumor necrosis factor-alpha, and interleukin-1 beta levels in neonatal late-onset sepsis. Mediators Inflamm 2008; 2008: 737141
32. Locksley RM. Nine lives: Plasticity among T helper cell subsets. J Experimental Med 2009; 206(8): 1643-1646
33. Huang W, Na L, Fidel PL et al. Requirement of interleukin-17a for systemic anti-candida albicans host defense in mice. J Infect Dis 2004; 190(3): 624-631
34. van de Veerdonk FL, Kullberg BJ, Verschueren IC et al. Differential effects of IL-17 pathway in disseminated candidiasis and zymosan-induced multiple organ failure. Shock 2010; 34(4): 407-411
35. De Luca A, Zelante T, D’Angelo C et al. IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol 2010; 3(4): 361-373
36. Conti HR, Shen F, Nayyar N et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Experimental Med 2009; 206(2): 299-311
37. Grimbacher B, Holland SM, Gallin JI et al. Hyper-IgE syndrome with recurrent infections-an autosomal dominant multisystem disorder. N Engl J Med 1999; 340(9): 692-702
38. Eyerich K, Foerster S, Rombold S et al. Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. J Invest Dermatol 2008; 128(11): 2640-2645
39. Bosmann M, Ward PA. Therapeutic potential of targeting IL-17 and IL-23 in sepsis. Clin Transl Med 2012; 1(1): 4
40. Pittet D, Monod M, Suter PM et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220(6): 751-758
41. Leon C, RuizSantana S, Saavedra P et al. Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009; 37(5): 1624-1633
42. Ostrosky-Zeichner L, Sable C, Sobel J et al. Multicenter prospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007; 26: 271-276
43. Posteraro B, De Pascale G, Tumbarello M et al. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of(1-3)-β-D-glucan assay, Candida score, and colonization index. Crit Care 2011; 15(5): R249
44. Presterl E, Lassnigg A, Mueller-Uri P et al. Cytokines in sepsis due to Candida albicans and in bacterial sepsis. Eur Cytokine Netw 1999; 10(3): 423-430
45. Rosentul DC, Plantinga TS, Scott WK et al. The impact of caspase-12 on susceptibility to candidemia. Eur J Clin Microbiol Infect Dis 2012; 31(3): 277-280
46. Gogos CA, Drosou E, Bassaris HP et al. Pro-versus antiinflammatory cytokine profile in patients with severe sepsis. a marker for prognosis and future therapeutic options. J Infect Dis 2000; 181(1): 176-180
47. Bozza FA, Salluh JI, Japiassu AM et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Critical Care 2007; 11(2): R49
48. Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993; 269(14): 1829-1835
49. Dinarello CA. Interleukin-1. Cytokine Growth Factors Rev 1997; 8(4): 253-265
50. Matuschak GM, Munoz C, Epperly NA et al. TNF-alpha and IL-6 expression in perfused rat liver after intraportal candidemia vs. E. coli or S.aureus bacteremia. Am J Physiol 1994; 267(2): R446-54
51. Matuschak GM, Lechner AJ. The yeast to hyphal transition following hematogenous candidiasis induces shock and organ injury independent of circulating tumor necrosis factor-alpha. Crit Care Med 1997; 25(1): 111-120
52. Cyktor JC, Turner J. Interleukin-10 and immunity against prokaryotic and eukaryotic intracellular pathogens. Infect Immun 2011; 79(8): 2964-2973
53. Heper Y, Akalın H, Mıstık R et al. Evaluation of serum Creactive protein, procalcitonin, tumor necrosis factor alpha, and interleukin-10 levels as diagnostic and prognostic parameters in patients with community-acquired sepsis, severe sepsis, and septic shock. Eur J Clin Microbiol Infect Dis 2006; 25(8): 481-491
54. Delsing CE, Gresnigt MS, Leentjens J et al. Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC Infect Dis 2014; 14: 166
55. Peck A, Mellins ED. Precarious balance: Th17 cells in host defense. Infect Immun 2010; 78(1): 32-38